Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Next-generation Sequencing

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Possible involvement of genome-wide near-haploidy and <i>MEN1</i> mutation in the molecular pathogenesis of pituitary carcinoma: Analysis by whole exome sequencing.

Neuro-oncology advances·2026

Same author

A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).

Japanese journal of clinical oncology·2026

Same author

Prediction of Overall Survival in Glioblastoma Using Early Postoperative Reduction in FLAIR Lesion Volume After Gross Total Resection.

Cancers·2026

Same author

Nationwide genomic data analysis of central nervous system tumors in Japan based on C-CAT database.

International journal of clinical oncology·2026

Same author

Comparing artificial intelligence and physician performance in predicting IDH mutation status in glioma.

NPJ digital medicine·2026

Same author

Significance of shunt placement for secondary communicating hydrocephalus in patients with high-grade glioma.

Journal of neuro-oncology·2026

Search research articles

Related Experiment Video

Updated: Oct 3, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

[Next-Generation Sequencing Tests for Malignant Brain Tumors].

Yoshitaka Narita¹

¹Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital.

No Shinkei Geka. Neurological Surgery

|February 16, 2022

Summary

Cancer genome-profiling tests identify tumor-specific genes in brain tumors. In Japan, insurance covers these tests for eligible patients, potentially expanding access to new clinical trial therapies.

Area of Science:

Oncology
Genomics
Medical Diagnostics

Background:

Cancer genome-profiling tests analyze tumor DNA to find specific mutations.
These tests are crucial for identifying actionable targets in cancer treatment.
In Japan, insurance coverage exists for malignant brain tumors but has limitations.

Purpose of the Study:

To evaluate the role and accessibility of cancer genome-profiling tests for malignant brain tumors.
To explore how expert panel findings can improve access to new therapies.
To address limitations in current insurance coverage for these tests.

Main Methods:

Next-generation sequencing (NGS) is used to analyze tumor tissue.
Analysis includes exome gene mutations, amplifications, deletions, and fusion gene expression.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Oct 3, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Patient eligibility criteria, such as performance status (PS), are considered.

Main Results:

The cancer genome-profiling test identifies tumor-specific driver genes.
Current insurance coverage in Japan is limited to patients with good performance status.
Expert panel findings are expected to broaden access to clinical trials.

Conclusions:

Cancer genome profiling is a key tool for personalized brain tumor treatment.
Expanding eligibility criteria can increase patient access to novel therapeutic agents.
Further research and policy adjustments are needed to optimize test utilization.